You are here: Industry Insights > Takeda

News List

Takeda and Frazier team up to launch biopharmaceutical firm pharmaceutical-technology
May 22, 2019
Takeda Pharmaceutical has collaborated with US-based Frazier Healthcare Partners to launch a biopharmaceutical company named Phathom Pharmaceuticals.
Takeda, Frazier Healthcare Partners to launch Phathom Pharma biospectrumasia
May 21, 2019
New Company and collaboration to develop Novel Therapeutics Including Vonoprazan for the Treatment of Acid-Related Disorders in North America and Europe
Takeda announces results of Phase 3b VARSITY studies biospectrumasia
May 20, 2019
VARSITY is a Phase 3b, randomized, double-blind, double-dummy, multi-center, active-controlled study to evaluate the efficacy and safety of vedolizumab intravenous (IV) compared to adalimumab subcutaneous (SC) at week 52 in patients with moderately to sev
Takeda and Frazier Healthcare Partners announce collaboration to launch Phathom Pharma biospectrumasia
May 20, 2019
New Company and collaboration to develop Novel Therapeutics Including Vonoprazan for the Treatment of Acid-Related Disorders in North America and Europe
Skyhawk, Takeda to Develop Neurological Disease Targets contractpharma
May 16, 2019
Skyhawk will use its SkySTAR platform to discover and develop small molecule treatments.
Novartis Buys Dry Eye Drug from Takeda for $5.3B contractpharma
May 16, 2019
Takeda also divests TachoSil to Ethicon for $400 million.
Takeda's BLA for Vedolizumab gets approval by U.S. FDA biospectrumasia
May 15, 2019
Takeda proposes to make vedolizumab SC available in both pre-filled syringe and pen options.
Takeda sells surgical patch to Ethicon for $400M biospectrumasia
May 13, 2019
Ethicon will acquire the assets and licenses that support the manufacturing, licensing and commercialization of TachoSil
Takeda taps Skyhawk's RNA-targeting tech for neurodegenerative disease fiercepharma
May 12, 2019
RNA biotech Skyhawk Therapeutics is inking another R&D deal—this time, it’s with Takeda Pharmaceutical, which wants to use the biotech’s platform to develop small molecules that correct RNA mis-splicing in neurodegenerative disease.
FDA Accepts Takeda’s BLA for a Subcutaneous Formulation of Vedolizumab americanpharmaceuticalreview
May 10, 2019
FDA Accepts Takeda’s BLA for a Subcutaneous Formulation of Vedolizumab.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page